Navigation Links
FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
Date:9/20/2007

Study Data Demonstrated Improved Progression-free Survival with Campath

CAMBRIDGE, Mass. and WAYNE, N.J., Sept. 20 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) and Bayer HealthCare Pharmaceuticals Inc. (NYSE: BAY) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) for Campath(R) (alemtuzumab) and granted regular approval for single-agent Campath for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). Campath was initially approved in 2001 under accelerated approval regulations and the FDA has determined that the study results submitted in the sBLA fulfill the post- marketing commitment to verify clinical benefit. A label expansion is under consideration in Europe.

"Campath is clearly an important single agent for the first-line treatment of CLL," said Peter Hillmen, MB, ChB, of the Leeds General Infirmary, Leeds, United Kingdom, and the lead investigator of the pivotal study comparing Campath against chlorambucil. "We are excited to be entering an era where our improved understanding of CLL, coupled with more advanced laboratory tests and targeted therapy options like Campath, have dramatically changed the first- line treatment approach for this type of leukemia."

Campath works in an entirely different way than chemotherapy, and is the first and only monoclonal antibody approved by the FDA for the treatment of B- CLL.

"The data that supported this label expa
'/>"/>

SOURCE Genzyme Corp. and Bayer HealthCare Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. UW-Madison approves new research institute
2. FDA approves GEs heart-imaging technology
3. Senate approves bill to expand stem cell funding
4. FDA approves advanced digital mammography system
5. Building commission approves Institutes for Discovery
6. UW Board of Regents approves $134 million medical research facility
7. FDA approves Bone Cares Hectorol for treatment of kidney disease
8. New Microarray Labeling Kit for Preparing cDNA Probes
9. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
10. aRNA Synthesis and Labeling for Array Analysis
11. Amino Allyl Labeling for Array Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... 28, 2015 First Harvest Financial ... leading source for advice to legal medical cannabis companies. ... and strategic planning to start-ups and entrepreneurs, First Harvest ... industry. , Wall Street veteran, Kevin Gillespie, has ... President and Portfolio Manager. Due to early success ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 Spartan Bioscience ... founder, has been selected by the Ottawa Chamber of ... 40. Dr. Lem was selected from over 240 applicants ... involvement. , Prior to Spartan, Dr. Lem founded Plexagen ... DNA Genotek. He holds a Medical Degree from the ...
(Date:4/28/2015)... 2015 The Alliance for Clinical ... non-profit organization dedicated to transforming the medical products ... system for clinical research, announced today that it ... type of clinical research event in Boston, October ... is changing,” said Greg Koski, PhD, MD, Co-founder ...
(Date:4/27/2015)... VANCOUVER , April 27, 2015 /PRNewswire/ - iCo ... ICOTF), today reported financial results for the year ... are expressed in Canadian dollars and presented under ... year,s phase two DME results did not provide ... but extremely undervalued assets remain at iCo Therapeutics", ...
Breaking Biology Technology:Leading Medical Cannabis Advisor, First Harvest Financial, Welcomes Top Executives Aboard 2Leading Medical Cannabis Advisor, First Harvest Financial, Welcomes Top Executives Aboard 3Spartan Bioscience Announces Paul Lem Named Ottawa’s Top 40 Under 40 2ACRES Announces Innovative Clinical Research Event--SYNERGY 2ACRES Announces Innovative Clinical Research Event--SYNERGY 3ACRES Announces Innovative Clinical Research Event--SYNERGY 4iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4
... Ventures, a venture capital,firm specializing in life science ... firm as its fourth partner. Broderick brings more,than ... fund,management, and technology commercialization. Before coming to ... in Milwaukee, WI, where he served on its ...
... EDT, EDMONTON, BELLEVUE, WASHINGTON, Sept. 12 /PRNewswire-FirstCall/ ... (the "Company") today announced that,the Company,s Board of ... of incorporation from the federal jurisdiction of Canada ... of America through a plan of,arrangement. Under the ...
... Inc., a,biotechnology company translating the complexity of human ... its president and,CEO, Dr. Keith O. Elliston, has ... Summit in Arlington, Va., September 17-18. Dr. ... on,"Enhancing Development and Commercial Value Added in Care ...
Cached Biology Technology:Dan Broderick Joins Prolog Ventures as Partner 2Dan Broderick Joins Prolog Ventures as Partner 3Biomira Announces Plan to Reincorporate in the United States 2Biomira Announces Plan to Reincorporate in the United States 3Biomira Announces Plan to Reincorporate in the United States 4Biomira Announces Plan to Reincorporate in the United States 5Biomira Announces Plan to Reincorporate in the United States 6Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit 2
(Date:3/24/2015)...   NexID Biometrics LLC, whose spoof-mitigation technology ... announced the beginning of shipments of version 2.0 of ... company, based in Potsdam, N.Y. , ... which began here today at the Walter E. Washington ... its SDK boosts the accuracy rate range to 96.5 ...
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
(Date:3/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces its biometric payment technology, ... featured in 2015 "I Want That" International CES Special, ... the DIY Network.   DIY,s "I Want ... site of the 2015 International CES for a firsthand ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... taken part in an international study which has discovered a ... of a region. And the secret lies in crushed ... been spent by researchers gathering, classifying and recording insects and ... region. Any changes to the biodiversity of that area could ...
... "Magic" mushrooms are well known for their hallucinogenic properties. ... development and how they should be classified in the ... evolutionary past of a fascinating fungi that has wide ... variety of medicinal applications. In the 19th ...
... Sciences Leopoldina and the Academy of Science of South Africa ... to a cooperation agreement signed in Pretoria by Leopoldina President ... of South Africa, Professor Daya Reddy. The Leopoldina ... Science of South Africa for many years, and the 2012/2013 ...
Cached Biology News:Insect 'soup' serving up rapid biodiversity monitoring 2Family matters: Evolutionary relationships among species of 'magic' mushrooms shed light on fungi 2Leopoldina signs cooperation agreement with the Academy of Science of South Africa 2
... Trap Time of Flight Mass Analyzer for superior sensitivity, mass accuracy, ... - 25,000 m/z, * Precursor ion selection range: 150 - 4000 ... 5 ppm with internal reference, * Dynamic range: 4 orders of ... ...
Four siRNAs targeting your gene of interest, providing gene silencing with 100% satisfaction guaranteed High knockdown potency , High specificity for minimal off-target effects , Flexible siR...
Mouse polyclonal antibody to BTAF1 - BTAF1 RNA polymerase II, B-TFIID transcription factor-associated, 170kDa (Mot1 homolog, S. cerevisiae)...
... series combines Harvard Apparatuss best pump mechanism, a ... range of configuration options. A lookup table in ... from all the major manufacturers. A bright, two ... information from across the lab. All models have ...
Biology Products: